Commonwealth Equity Services’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Commonwealth Equity Services’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$933K	Sell	27,651 -17	-0.1%	-$510	﹤0.01%	2763
2026 Q1	$804K	Sell	27,668 -187	-0.7%	-$5.43K	﹤0.01%	2796
2025 Q4	$730K	Sell	27,855 -336	-1%	-$8.64K	﹤0.01%	2846
2025 Q3	$666K	Sell	28,191 -3,011	-10%	-$66.6K	﹤0.01%	2946
2025 Q2	$640K	Buy	31,202 +490	+2%	+$9.87K	﹤0.01%	2956
2025 Q1	$629K	Buy	30,712 +1,048	+4%	+$23.4K	﹤0.01%	2846
2024 Q4	$671K	Sell	29,664 -5,225	-15%	-$125K	﹤0.01%	2735
2024 Q3	$859K	Sell	34,889 -16,105	-32%	-$392K	﹤0.01%	2466
2024 Q2	$1.18M	Sell	50,994 -59	-0.1%	-$1.38K	﹤0.01%	2152
2024 Q1	$1.23M	Buy	51,053 +563	+1%	+$13.2K	﹤0.01%	2102
2023 Q4	$1.16M	Sell	50,490 -1,607	-3%	-$32.3K	﹤0.01%	2069
2023 Q3	$1.06M	Buy	52,097 +1,840	+4%	+$41.3K	﹤0.01%	2033
2023 Q2	$1.17M	Buy	50,257 +2,417	+5%	+$58K	﹤0.01%	1980
2023 Q1	$1.11M	Sell	47,840 -30,957	-39%	-$774K	﹤0.01%	1971
2022 Q4	$1.98M	Sell	78,797 -23,370	-23%	-$628K	﹤0.01%	1505
2022 Q3	$2.7M	Buy	102,167 +56,410	+123%	+$1.74M	0.01%	1235
2022 Q2	$1.32M	Buy	45,757 +2,805	+7%	+$83.7K	﹤0.01%	1684
2022 Q1	$1.48M	Buy	42,952 +20,868	+94%	+$737K	﹤0.01%	1699
2021 Q4	$967K	Buy	22,084 +3,340	+18%	+$158K	﹤0.01%	2014
2021 Q3	$950K	Buy	18,744 +1,061	+6%	+$55.3K	﹤0.01%	1960
2021 Q2	$920K	Buy	17,683 +3,390	+24%	+$159K	﹤0.01%	1974
2021 Q1	$653K	Buy	14,293 +4,002	+39%	+$196K	﹤0.01%	2118
2020 Q4	$472K	Buy	10,291 +2,009	+24%	+$86.7K	﹤0.01%	2187
2020 Q3	$322K	Buy	+8,282	New	+$318K	﹤0.01%	2300

Other funds holding IDNA

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $1.05B AUM 18.22% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Trek Financial Scottsdale, Arizona $2.01B AUM 53.49% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Commonwealth Equity Services's IDNA Position: Q2 2026 in Review

Commonwealth Equity Services reduced its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 0.06% in Q2 2026, selling an estimated $510 and leaving 27,651 shares worth $933K. The position accounts for ﹤0.01% of the portfolio, ranked #2763.

Commonwealth Equity Services first reported a position in IDNA in Q3 2020 and has held it in 24 quarters since. The position peaked at $2.7M in Q3 2022. 65 funds tracked by Wall St. Rank hold IDNA as of Q2 2026.

Commonwealth Equity Services held 27,651 shares of iShares Genomics Immunology and Healthcare ETF worth $933K as of Q2 2026.
Commonwealth Equity Services sold 17 iShares Genomics Immunology and Healthcare ETF shares in Q2 2026, an estimated $510.
iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #2763 holding.
Commonwealth Equity Services first reported a position in iShares Genomics Immunology and Healthcare ETF in Q3 2020 and has held it in 24 quarters since.
Commonwealth Equity Services's iShares Genomics Immunology and Healthcare ETF position peaked at $2.7M in Q3 2022.
65 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.